Expert consensus on clinical diagnosis and treatment of bone metastases and bone-related diseases of prostate cancer (2021 edition).
10.3760/cma.j.cn112152-20210714-00513
- Collective Name:Genitourinary Oncology Committee of Chinese Anti-cancer Association
- Publication Type:Journal Article
- Keywords:
Bone metastasis;
Bone-modifying drugs;
Multidisciplinary strategies;
Prostate neoplasms
- MeSH:
Bone Neoplasms;
Bone and Bones;
Consensus;
Humans;
Male;
Prostatic Neoplasms/diagnosis*;
Spinal Cord Compression/etiology*
- From:
Chinese Journal of Oncology
2021;43(10):1016-1026
- CountryChina
- Language:Chinese
-
Abstract:
The morbidity and mortality of prostate cancer ascend yearly, which seriously threatens the health of the male population. Bone is the main metastasis site of prostate cancer, with bone metastases and skeletal-related events (SREs) occuring in more than 70% of patients with advanced prostate cancer. Bone metastases and the resulting SREs, such as spinal cord compression and pathological fracture, seriously affect the life quality of the patients. Although the active treatments of the primary disease is important, the application of bone-modifying agents to prevent SREs cannot be overlooked. However, there is no standard treatment procedure for the bone metastasis of prostate cancer at present. According to the clinical status, the Genitourinary Oncology Committee of Chinese Anti-cancer Association formulated this consensus, which integrated clinical evidence and real world clinical practices in China and abroad, to help clinicians make more accurate diagnosis and treatment for the bone metastases of prostate cancer with multidisciplinary strategies.
